FrancophonIA/ELRC3.0 huggingface dataset:
English: • antiviral medicine used to treat chronic hepatitis C virus (HCV) infection in adults (e.g. glecaprevir/pibrentasvir, simeprevir and sofosbuvir/velpatasvir/voxilaprevir );
Estonian: - mittenukleosiidsed pöördtranskriptaasi inhibiitorid (NNRTId) (sh efavirens, nevirapiin); - suukaudsed rasestumisvastased preparaadid või rasestumisvastane plaaster (vt lõik
English: The concomitant administration with lurasidone is contraindicated (see section 4.3).
Estonian: Kaletra ja lurasidooni samaaegne manustamine on vastunäidustatud (vt lõik 4.3).
English: (Lopinavir/ritonavir 400/100 mg BID, multiple dose)
Estonian: (Lopinaviir/ritonaviir 400/100 mg kaks korda ööpäevas, korduvad annused)
English: Tip
Estonian: Tootja
English: Serum concentrations may be increased due to CYP3A inhibition by ritonavir.
Estonian: Seerumi kontsentratsioonid võivad suureneda tulenevalt lopinaviiri/ritonaviiri CYP3A inhibeerivast toimest.
English: Film-coated tablet Yellow debossed with [Abbott logo] and “KA”.
Estonian: Õhukese polümeerikattega tablett Kollast värvi tabletid, millel on pimetrükis Abbotti logo ja tähis “KA”.
English: Paediatric dosing guidelines with concomitant efavirenz or nevirapine
Estonian: Annustamisjuhised lastel efavirensi või nevirapiiniga kooskasutamisel
English: • decreased ability of the body to handle sugar including diabetes mellitus, weight loss;
Estonian: söögiisu vähenemine, refluks maost söögitorusse, mis võib põhjustada valu;
English: The safety and efficacy of Kaletra has not been established in patients with significant underlying liver disorders.
Estonian: Kaletra ohutus ja efektiivsus väljendunud maksahäirete korral ei ole kindlaks tehtud.
English: GI motility agent Cisapride
Estonian: Seedetrakti motiilsust suurendavad ained Tsisapriid
English: Ethinyl Oestradiol: ↓
Estonian: KG Knollstrasse
English: Delamanid (100 mg BID)
Estonian: Delamaniid (100 mg kaks korda ööpäevas)
English: Hepatic Insufficiency
Estonian: Vähivastased ained Neratiniib
English: Kaletra must not be administered once daily in combination with phenytoin.
Estonian: Kaletra ja fenütoiini kombinatsiooni ei tohi manustada üks kord ööpäevas.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the reported time to onset is more variable and can occur many months after initiation of treatment.
Estonian: Samuti on teatatud, et immuunrekonstitutsiooni tingimustes on esinenud autoimmuunhäireid (nt Graves'i tõbi ja autoimmuunne hepatiit).
English: 7.5 mg/ml Solution for injection
Estonian: 7,5 mg/ml Süstelahus
English: Intramuscular use vial (glass)
Estonian: Viaal (klaas)
English: This variation was to be recognised in Austria, Belgium, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden and the United Kingdom
Estonian: Seda muudatust oleks pidanud tunnustama Austria, Belgia, Hispaania, Iirimaa, Itaalia, Kreeka, Luksemburg, Madalmaad, Portugal, Prantsusmaa, Rootsi, Saksamaa, Soome ja Ühendkuningriik (asjaomased liikmesriigid).
English: Outcome of a procedure under Article 6(12) of Regulation (EC) 1084/2003 as amended
Estonian: Muudetud määruse (EÜ) nr 1084/2003 artikli 6 lõike 12 alusel toimunud menetluse tulemus
English: The European Commission issued a decision on 02 September 2010.
Estonian: Euroopa Komisjon võttis oma otsuse vastu 02. septembril 2010.
English: The Committee looked at the studies presented by the company to support the new indication.
Estonian: Komitee vaatas üle uuringud, mille ettevõte oli esitanud uue näidustuse toetamiseks.
English: 1 In all other Member States of the EU, the medicine has received a marketing authorisation at national level.
Estonian: 1 Kõikides teistes ELi liikmesriikides on ravim saanud müügiloa riigi tasandil.
English: What is Genotropin?
Estonian: Mis on Genotropin?
English: Co-rapporteur(s):
Estonian: Kaasettekandja(d):
English: Why was Genotropin reviewed?
Estonian: Miks Genotropini taotlus uuesti üle vaadati?
English: Because the Member States were not able to reach an agreement, the Netherlands referred the matter to the CHMP for arbitration on 28 October 2009.
Estonian: Et liikmesriigid ei suutnud jõuda kokkuleppele, suunas Holland 28. oktoobril 2009 küsimuse inimravimite komiteele vahekohtumenetluseks.
English: The Committee concluded that the change to the marketing authorisation cannot be granted.
Estonian: Komitee otsustas, et müügiloa muutmist ei saa lubada.
English: Another point was the fact that the company had presented too few data on the final height reached by the patients in the studies.
Estonian: Teisena toonitati tõsiasja, et ettevõte oli esitanud liiga vähe andmeid lõpliku pikkuse kohta, milleni uuringus osalenud patsiendid olid kasvanud.
English: Genotropin, also marketed under the trade name Genotonorm, is available throughout the European Union (EU).
Estonian: Genotropin, mida turustatakse ka kaubamärgi Genotonorm all, on müügil kogu Euroopa Liidu territooriumil.
English: In 15 Member States of the EU, Genotropin is authorised under a mutual recognition procedure on the basis of the initial authorisation granted by Denmark on 7 May 19871.
Estonian: Euroopa Liidu 15 liikmesriigis on Genotropini lubatud müüa vastastikuse tunnustamise menetluse alusel vastavalt Taanis 7. mail 19871 välja antud esialgsele müügiloale.
English: These national marketing authorisations are not affected by this referral.
Estonian: Käesolev esildis ei mõjuta neid riiklikke müügilubasid.
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the variation to the marketing authorisation for Genotropin cannot be approved in Denmark as well as in all concerned Member States.
Estonian: Kättesaadavatele andmetele ja komitees toimunud teaduslikule arutelule tuginedes otsustas inimravimite komitee, et Genotropini müügiloa muudatusele ei saa anda heakskiitu Taanis ega üheski asjaomases liikmesriigis.
English: In July 2008, Pfizer applied for a change (variation) to the marketing authorisation to add a new indication in Denmark (the ‘reference Member State').
Estonian: 2008. aasta juunis taotles Pfizer Taanis (viiteliikmesriigis) müügiloa muutmist, et lisada sellesse uus näidustus.
English: 25 January 2010, 3 May 2010 and 24 May 2010
Estonian: 25. jaanuar 2010, 3. mai 2010 ja 24. mai 2010
English: The company that makes the medicine is Pfizer.
Estonian: Ravimit toodab ettevõte Pfizer.
English: 24 June 2010
Estonian: 24. juuni 2010
English: The European Medicines Agency has completed an arbitration procedure for Genotropin and associated names.
Estonian: Euroopa Ravimiamet on viinud lõpule Genotropini ja sarnase nimetusega ravimite vahekohtumenetluse.
English: 02 September 2010
Estonian: 02. septembril 2010
English: Growth hormone promotes growth during childhood and adolescence, and also acts on the way the body handles proteins, fat and carbohydrates.
Estonian: Kasvuhormoon soodustab lapse- ja noorukieas kasvu ning see mõjutab ka viisi, kuidas organism töötleb valke, rasvu ja süsivesikuid.
English: Somatropin is produced by a method known as ‘recombinant DNA technology': it is made by an organism that has received a gene (DNA), which makes it able to produce growth hormone.
Estonian: Somatropiini valmistatakse rekombinant-DNA-tehnika abil: seda valmistab organism, millesse on viidud kasvuhormooni tootmist võimaldav geen (DNA).
English: It also looked at published information on the use of growth hormone in patients with JIA, and convened a meeting of experts, which included experts both in the treatment of hormonal disorders (endocrinologists) and in the treatment of joint diseases (rheumatologists).
Estonian: Komitee vaatas üle ka juba avaldatud teabe kasvuhormooni kasutamise kohta lapseea idiopaatilise artriidiga patsientidel ja korraldas ekspertide kokkusaamise, kuhu olid kaasatud nii hormonaalsete häirete ravi eksperdid (endokrinoloogid) kui ka liigesehaiguse ravi eksperdid (reumatoloogid).
English: Procedure start date:
Estonian: Menetluse alguskuupäev:
English: It is also used to correct short height in children who have the genetic diseases Turner syndrome and Prader Willi syndrome, and in children who have longstanding kidney problems.
Estonian: Seda kasutatakse ka lühikese kasvu korrigeerimiseks lastel selliste geneetiliste haigustega nagu Turneri sündroom ja Prader-Willi sündroom, samuti kauakestvate neeruhaigustega laste ravis.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to arbitrate on a change to the marketing authorisation for Genotropin to include a new indication for the treatment of stunted growth caused by the long-term use of steroids in children with juvenile idiopathic arthritis.
Estonian: Ravimiameti inimravimite komiteed on palutud vahekohtunikuks Genotropini müügiloa muutmisel uue näidustuse lisamisega, mis hõlmab pikaajalisest steroidide kasutamisest tingitud kasvupeetuse ravi lapseea idiopaatilise artriidiga lastel.
English: Genotropin is used as replacement therapy in children and adults who have a growth hormone deficiency.
Estonian: Genotropini kasutatakse asendusravina kasvuhormooni puudulikkusega lastel ja täiskasvanutel.
English: The grounds for the referral were that fewer patients currently need to use steroids than in the past, because other medicines that do not affect growth have become available to control JIA.
Estonian: Esildise aluseks oli steroidide kasutamist vajavate patsientide hulga vähenemine võrreldes varasemaga, sest lapseea idiopaatilise artriidi kontrolli all hoidmise jaoks on muutunud kättesaadavaks teised ravimid, mis ei mõjuta kasvu.
English: Genotropin is a medicine that contains somatropin, which is a copy of natural growth hormone.
Estonian: Genotropin on ravim, mis sisaldab somatropiini.
English: Company responses provided on:
Estonian: Ettevõtte vastuste laekumise kuupäevad:
English: Rapporteur:
Estonian: Ettekandja:
English: The new indication was the use of Genotropin in children on long-term treatment with steroids for juvenile idiopathic arthritis (JIA), a rare childhood disease causing inflammation of many joints.
Estonian: Genotropini uus näidustus oli ravimi kasutamine mitme liigese põletikku põhjustava haruldase lastehaiguse lapseea idiopaatilise artriidiga laste pikaajaliseks steroidravi korral.
English: Genotropin was to be used to improve growth and body composition in children with severe JIA in whom the prolonged use of steroids to help control inflammation had led to a slowing down of growth.
Estonian: oleks kasutatud kasvu soodustamiseks ja kehaehituse parandamiseks raskekujulise lapseea idiopaatilise artriidiga lastel, kellel põletike kontrolli all hoidmiseks pikka aega kasutatud steroidid on põhjustanud kasvu aeglustumist.
English: • Parkinson's disease.
Estonian: • Parkinsoni tõbi.
English: This summary was last updated in 02-2013.
Estonian: Kokkuvõtte viimane uuendus: 02-2013.
English: The dose can then be increased every week until an effective dose is reached.
Estonian: Annust võib seejärel igal nädalal suurendada, kuni saavutatakse efektiivne annus.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Leganto on 16 June 2011.
Estonian: Euroopa Komisjon andis Leganto müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. juunil
English: The full EPAR for Leganto can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Leganto kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The same place must not be used again until two weeks later.
Estonian: Samale manustamiskohale ei või plaastrit uuesti asetada enne kui kahe nädala pärast.
English: Leganto is applied once a day at about the same time every day.
Estonian: Legantot kasutatakse üks kord ööpäevas, iga päev ligikaudu samal ajal.
English: The patients then lose their ability to control their movements reliably.
Estonian: Selle tagajärjel ei suuda patsient liigutusi enam usaldusväärselt juhtida.
English: Leganto is used when a specific cause for the disorder cannot be identified.
Estonian: Legantot kasutatakse, kui häire konkreetset põhjust ei ole võimalik kindlaks määrata.
English: Other information about Leganto
Estonian: Muu teave Leganto kohta
English: This medicine is the same as Neupro, which is already authorised in the European Union (EU).
Estonian: See ravim on samane Neuproga, millel juba on Euroopa Liidus müügiluba.
English: The way rotigotine works in restless legs syndrome is not fully understood.
Estonian: Rotigotiini toimemehhanism rahutute jalgade sündroomi korral ei ole täielikult teada.
English: Each patch releases 1, 2, 3, 4, 6 or 8 mg of the active substance rotigotine over 24 hours.
Estonian: Igast plaastrist vabaneb 24 tunni jooksul 1, 2, 3, 4, 6 või 8 mg toimeainet rotigotiini.
English: The patch remains on the skin for 24 hours and is then replaced by a new one in a different place.
Estonian: Plaaster jäetakse nahale 24 tunniks ja seejärel asendatakse uue plaastriga, mis asetatakse mõnda teise kohta.
English: Leganto is used to treat the symptoms of the following diseases in adults:
Estonian: Legantot kasutatakse järgmiste haiguste sümptomite ravimiseks täiskasvanutel:
English: EPAR summary for the public rotigotine
Estonian: Kokkuvõte üldsusele rotigotiin
English: The backing layer of Leganto contains aluminium.
Estonian: Leganto aluskiht sisaldab alumiiniumi.
English: The strength of patch to use at the start of treatment depends on the type and stage of the disease being treated.
Estonian: Ravi alguses kasutatava plaastri tugevus sõltub ravitava haiguse liigist ja staadiumist.
English: The company that makes Neupro has agreed that its scientific data can be used for Leganto (‘informed consent').
Estonian: Neupro tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Leganto toetuseks (teabel põhinev nõusolek).
English: The CHMP decided that Leganto's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Leganto kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The decrease seen with Leganto was similar to that seen with pramipexole (2.8 h).
Estonian: Legantoga saavutatud vähenemine oli sarnane pramipeksooliga saavutatuga (2,8 h).
English: • moderate to severe restless legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night.
Estonian: • mõõdukas või raske rahutute jalgade sündroom, mille korral on patsiendil tahtele allumatu vajadus jalgu liigutada, et vaigistada ebamugavat, valulikku või ebatavalist aistingut, tavaliselt öösiti.
English: What is Leganto?
Estonian: Mis on Leganto?
English: The main measure of effectiveness was the change in symptoms after six months of treatment with a stable dose, measured using two standard scales.
Estonian: Efektiivsuse põhinäitaja oli 6-kuulise püsiva annusega ravi järel toimunud sümptomite muutus, mida mõõdeti kahe standardskaala alusel.
English: Dopamine is a messenger substance in the parts of the brain that control movement and co-ordination.
Estonian: Dopamiin toimib virgatsainena aju osades, mis juhivad liigutusi ja koordinatsiooni.
English: Why has Leganto been approved?
Estonian: Miks Leganto heaks kiideti?
English: Rotigotine then stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson's disease, such as stiffness and slowness of movement.
Estonian: Rotigotiin stimuleerib aju samamoodi kui dopamiin, nii et patsient suudab oma liigutusi juhtida ning Parkinsoni tõve nähte ja sümptomeid, nagu kangestust ja liigutuste aeglust, esineb vähem.
English: For more information about treatment with Leganto, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Legantoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In smaller studies completed later, the effectiveness of Leganto was found to be comparable with ropinirole.
Estonian: Hiljem tehtud väiksemates uuringutes oli Leganto efektiivsus võrreldav ropinirooli efektiivsusega.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Leganto.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Leganto was less effective than ropinirole: an improvement was seen in 70% of the patients receiving ropinirole.
Estonian: Leganto oli ropiniroolist vähem efektiivne: ropinirooliga vähenesid sümptomid 70%-l patsientidest.
English: Leganto is used on its own in early-stage disease, or in combination with levodopa (another medicine used in Parkinson's disease) at any stage of the disease, including the later stages when levodopa starts becoming less effective;
Estonian: Legantot kasutatakse ainsa ravimina varases järgus Parkinsoni tõve raviks või koos levodopaga (samuti Parkinsoni tõve ravim) haiguse mis tahes järgus, sealhulgas hilisstaadiumis, kui levodopa efektiivsus hakkab vähenema;
English: Leganto must not be used in people who are hypersensitive (allergic) to rotigotine or any of the other ingredients.
Estonian: Legantot ei tohi kasutada patsiendid, kes on rotigotiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Leganto delivers a constant supply of rotigotine through the skin into the bloodstream.
Estonian: Leganto eraldab läbi naha vereringesse pidevalt rotigotiini.
English: In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases.
Estonian: Parkinsoni tõvega patsiendil hakkavad dopamiini tootvad rakud hävima ning dopamiini hulk ajus väheneb.
English: The syndrome is thought to be caused by problems in the way dopamine works in the brain, which may be improved by rotigotine.
Estonian: Arvatakse, et seda sündroomi põhjustavad probleemid, mis on seotud dopamiini toimimisviisiga ajus, ja rotigotiin võib neid leevendada.
English: In moderate to severe restless legs syndrome, Leganto has been compared with placebo in two main studies involving a total of 963 patients.
Estonian: Rahutute jalgade mõõduka kuni raske sündroomi korral võrreldi Legantot platseeboga kahes põhiuuringus, milles osales kokku 963 patsienti.
English: This is a summary of the European public assessment report (EPAR) for Leganto.
Estonian: See on ravimi Leganto Euroopa avaliku hindamisaruande kokkuvõte.
English: Leganto was more effective than placebo in treating Parkinson's disease.
Estonian: Leganto oli Parkinsoni tõve ravis efektiivsem kui platseebo.
English: In Parkinson's disease, Leganto has been compared with placebo (a dummy treatment) in four studies involving 830 patients with early-stage disease and 842 patients with advanced disease.
Estonian: Parkinsoni tõve ravis võrreldi Legantot platseeboga (näiv ravim) neljas uuringus, milles osales 830 varajases ja 842 hilises staadiumis haigusega patsienti.
English: What is the risk associated with Leganto?
Estonian: Mis riskid Legantoga kaasnevad?
English: Two of these studies also compared Leganto with other dopamine agonists (ropinirole in early-stage disease and pramipexole in advanced disease).
Estonian: Neist kahes uuringus võrreldi Legantot ka dopamiini teiste agonistidega (haiguse varajase järgu korral ropinirooliga ja hilise järgu korral pramipeksooliga).
English: For restless legs syndrome, the maximum dose is 3 mg/24 h.
Estonian: Rahutute jalgade sündroomi maksimaalne raviannus on 3 mg ööpäevas.
English: The most common side effects with Leganto in patients with Parkinson's disease (seen in more than 1 patient in 10) are somnolence (sleepiness), dizziness, headache, nausea (feeling sick), vomiting, and application site reactions such as redness, itching and irritation of the skin.
Estonian: Parkinsoni tõvega patsientidel olid Leganto kasutamise kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) unisus, peapööritus, peavalu, iiveldus, oksendamine ja manustuskoha reaktsioonid, näiteks punetus, sügelus ja naha ärritus.
English: In early-stage disease, 48 to 52% of the patients using Leganto had an improvement in symptoms, compared with 19 to 30% of those using placebo.
Estonian: Haiguse varajases järgus leevenesid sümptomid Leganto kasutamisel 48-52%-l patsientidest, platseebo kasutamisel aga 19-30%-l patsientidest.
English: In patients with restless legs syndrome, the most common side effects (seen in more than 1 patient in 10) are nausea, application site reactions, asthenic conditions (conditions such as tiredness, weakness and feeling unwell) and headache.
Estonian: Rahutute jalgade sündroomiga patsientide kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on iiveldus, manustuskoha reaktsioonid, asteenilised nähud (väsimus, nõrkus, halb enesetunne) ja peavalu.
English: For the full list of all side effects reported with Leganto, see the package leaflet.
Estonian: Leganto kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The studies in early-stage disease looked at the number of patients who had at least a 20% improvement in symptoms, as measured with a standard symptom questionnaire.
Estonian: Haiguse varajase staadiumi uuringutes jälgiti standardküsitlusega, kui paljudel patsientidel paranesid sümptomid vähemalt 20% võrra.
English: To avoid skin burns, Leganto must be removed if the patient has to have magnetic resonance imaging (MRI) or cardioversion (a process that restores the heart's normal rhythm).
Estonian: Kui patsiendile on vaja teha magnetresonantstomograafia (MRI) või kardioversioon (normaalse südamerütmi taastamise protseduur), tuleb Leganto nahapõletuste vältimiseks eemaldada.
English: Leganto is a range of transdermal patches (patches that deliver a medicine across the skin).
Estonian: Legantot turustatakse mitmesuguste transdermaalsete plaastritena (plaaster, millest ravim imbub organismi läbi naha).
English: The maximum dose is 8 mg/24 h for early-stage Parkinson's disease and 16 mg/24 h for advanced disease.
Estonian: Varases staadiumis Parkinsoni tõve maksimaalne raviannus on 8 mg ööpäevas ja haiguse hilises järgus on maksimaalne annus 16 mg ööpäevas.
English: The active substance in Leganto, rotigotine, is a dopamine agonist, which means that it imitates the action of dopamine.
Estonian: Leganto toimeaine rotigotiin on dopamiini agonist, st sellel on dopamiiniga analoogne toime.
English: How does Leganto work?
Estonian: Kuidas Leganto toimib?
English: In advanced Parkinson's disease, patients using Leganto had a greater decrease in their ‘off' time than those taking placebo (a decrease of 2.1 to 2.7 h with Leganto compared with 0.9 h with placebo).
Estonian: Haiguse hilises järgus Legantot kasutanud patsientidel vähenes passiivse seisundi kestus rohkem kui platseebot saanud patsientidel (Legantoga 2,1-2,7 h ja platseeboga 0,9 h).
English: What benefit has Leganto shown during the studies?
Estonian: Milles seisneb uuringute põhjal Leganto kasulikkus?
English: The patch is applied to dry, clean, healthy skin on the abdomen (tummy), thigh, hip, side, shoulder or upper arm.
Estonian: Plaaster asetatakse kõhu, reie, puusa, külje, õla või õlavarre puhtale kuivale tervele nahale.
English: In restless legs syndrome, patients using doses of Leganto between 1 and 3 mg/24 h had a greater improvement than those using placebo in the two studies, as measured on both symptom scales.
Estonian: Rahutute jalgade sündroomi ravis paranesid Legantot annuses 1 ja 3 mg ööpäevas võtnud patsientide näidud mõlemal sümptomite skaalal rohkem kui platseebot saanud patsientidel.